Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.68 |
| ▸ | AR | P10275 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.66 |
| ▸ | HTR2B | P41595 | 1/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 17/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14981310 | 0.83 | PGR (0.88) | PGRARLMNAABCC4ABCB11 | |
| SCHEMBL3747286 | 0.83 | CYP19A1 (0.60) | PGRARLMNAABCC4ABCB11 | |
| SCHEMBL13046011 | 0.83 | PGR (0.62) | PGRARLMNAABCC4ABCB11 | |
| SCHEMBL14256372 | 0.82 | PGR (0.80) | PGRARLMNAABCC4ABCB11 | |
| SCHEMBL13681411 | 0.81 | PGR (1.00) | PGRARLMNAABCC4ABCB11 | |
| SCHEMBL13093754 | 0.81 | PGR (0.65) | PGRARLMNAABCC4ABCB11 | |
| SCHEMBL12558847 | 0.81 | PGR (0.65) | PGRARLMNAABCC4ABCB11 | |
| Drospirenone SCHEMBL14227067 | 0.80 | PGR (1.00) | PGRARLMNAABCC4ABCB11 | |
| Drospirenone SCHEMBL13845352 | 0.80 | PGR (1.00) | PGRARLMNAABCC4ABCB11 | |
| Drospirenone SCHEMBL18717263 | 0.80 | PGR (1.00) | PGRARLMNAABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | HSD17B11, HSD17B7, NR5A1 | PGR 61/4885AR 73/4885LMNA 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.